Germany's Merck lowers full-year performance expectations

German pharmaceutical giant Merck Group announced a downward revision of its full-year profit guidance amid multiple pressures such as unclear macroeconomic conditions, geopolitical uncertainties, and exchange rate fluctuations. The Merck Group expects its adjusted earnings before interest, taxes, depreciation, and amortization for 2025 to be in the range of 5.8 billion to 6.4 billion euros, lower than the forecast of 6.1 billion to 6.6 billion euros in February.